ulocuplumab
mAbexperimental
Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies. Ulocuplumab targets CXCR4. — Wikipedia
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01120457)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaUlocuplumab ↗
- ChEMBLCHEMBL3039543 ↗
Also known as
- bms-936564
- bms-936564
- bms-936564
- mdx-1338
- mdx-1338
- ulocuplumab
- ulocuplumab
- ulocuplumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03225716 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2017 | Bristol-Myers Squibb, Harvard University |
| NCT02666209 | N/A | Jan 22, 2016 | Bristol-Myers Squibb, Harvard University |
| NCT02472977 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | Bristol-Myers Squibb |
| NCT02305563 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2015 | Bristol-Myers Squibb |
| NCT01359657 | Phase 1 | Sep 1, 2011 | Bristol-Myers Squibb |
| NCT01120457 | Phase 1 | Aug 1, 2010 | Bristol-Myers Squibb |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 6 | 4 | 3 | 2010 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2016 |
2 organizations
Page 1 / 1